ホルモン不応性前立腺癌に対するIFM療法およびVIP療法

Abstract

再燃およびホルモン無効性前立腺癌患者19名に対しIFM療法・VIP療法を施行した.1) IFM療法では, 排尿障害は25%に, 疼痛は44%に, VIP療法では, それぞれ33%, 63%に改善をみた.2)総合効果は, IFM療法では, 志田らの基準で20%, Karnofskyの基準で0%, NPCPの基準で50%, 小山・斎藤班の基準で0%であり, VIP療法ではそれぞれ, 30%, 30%, 70%, 10%であった.3)副作用は両療法とも軽いものが多く, 使用しやすいregimenであると思われた.4)予後は, 両療法を施行されたグループとも10ヵ月での生存率は約20%と低く, さらに有効な化学療法の開発が必要と考えられた

Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP). Nine of them were treated with IFM, and nine with VIP, and one with IFM and also VIP. In the case of the IFM therapy, the over-all response rate was 0% by the Karnofsky's category of response, 20% by the response criteria of Shida et al., 50% by the National Prostatic Cancer Project (NPCP) criteria, and 0% by the response criteria of Koyama and Saito. In the case of the VIP therapy, the over-all response rate was 30% by the Karnofsky's category, 30% by the response criteria of Shida et al., 70% by the NPCP criteria and 20% by the response criteria of Koyama and Saitoh. The one-year survival rates of these patients treated with IFM and VIP were both about 20%. Only one patient treated with VIP therapy showed a partial response. Therefore, a more effective regimen for hormonal refractory adenocarcinoma of the prostate must be developed.